Acute promyelocytic leukemia (APL) showing PML-RARA are treated on ATRA- and anthracycline-based or ATRA- and arsenic trioxide-based protocols, whereas the core binding factor (CBF) leukemias with RUNX1-RUNX1T and CBFB-MYH11 are treated with intensive chemotherapy involving cytarabine and are characterized by relatively favorable prognosis [2]. This evidence concerns the gene RUNX1 and acute promyelocytic leukemia.